Insomnia - natural ways to sleep without pills (2026)

Complaints about sleep are reported by half of adult Poles, but only a portion of them meet the criteria for insomnia as a disorder. This difference determines what to seek: immediate support or treatment. Scientific societies have been answering this question the same way for years, and the answer rarely makes it into guides because it cannot be bought in a capsule. In this guide, we go through the interventions listed in the guidelines and meta-analyses, providing details on what exactly was measured: how many studies, how many participants, how large the effect was, and the quality of the evidence. Several popular statements about sleep hygiene, melatonin, and valerian did not survive such scrutiny, and we state directly which ones and why.

KEY INFORMATION
- Multi-component cognitive-behavioral therapy for insomnia has a strong recommendation in the guidelines, as the only behavioral intervention (Edinger et al., American Academy of Sleep Medicine, 2021).
- The same guidelines suggest NOT using sleep hygiene alone as a standalone treatment for chronic insomnia.
- The pharmacological guidelines from 2017 suggest not using melatonin, valerian, or tryptophan for chronic insomnia (Sateia et al., 2017).
- In a meta-analysis of three studies, magnesium shortened the time to fall asleep by 17.36 minutes, but the increase in sleep duration of 16 minutes was not statistically significant, and the quality of evidence was rated as low to very low.
- Snoring with apnea, daytime sleepiness despite a full night’s sleep, and persistent leg discomfort in the evening are reasons to see a doctor instead of seeking a supplement.

How common is insomnia in Poland?

Complaints about sleep are reported by every second adult. In the NATPOL study, conducted on a representative sample of 2413 people aged 18 to 79, 50.5% of respondents reported sleep issues, including 58.9% of women and 41.4% of men (Nowicki i wsp., Psychiatria Polska, 2016). The highest percentage, 74.8%, was recorded among women aged 60 to 79.

However, a complaint about sleep is not the same as a diagnosis. Insomnia as a disorder requires difficulties in falling asleep, maintaining sleep, or waking up too early, occurring regularly for many weeks and causing a decline in daytime functioning. Without this second condition, we are dealing with shorter sleep, not a disease. A person who rejuvenates in six hours and does not feel it during the day does not need treatment.

The distinction has practical implications. Short-term insomnia, related to stress or lifestyle changes, usually resolves after the cause disappears. Chronic insomnia is a separate diagnosis, and it is this that the guidelines discussed later in the text pertain to.

It is also worth knowing the stakes. A meta-analysis of twenty-one longitudinal studies found that individuals without depression who reported insomnia had a twofold higher risk of developing depression in follow-up. The odds ratio was 2.60 with a confidence interval from 1.98 to 3.42 (Baglioni i wsp., Journal of Affective Disorders, 2011). The authors propose that early treatment of insomnia should be considered a component of mental health protection.

Why is cognitive-behavioral therapy a first-line treatment?

Because as the only behavioral intervention, it received a strong recommendation. The guidelines from the American Academy of Sleep Medicine, developed using the GRADE method, recommend the use of multi-component cognitive-behavioral therapy for insomnia in adults with chronic insomnia and designate this recommendation as strong, meaning it should be implemented by physicians in most situations (Edinger i wsp., Journal of Clinical Sleep Medicine, 2021).

All other items from these guidelines have a conditional recommendation, which is weaker and requires consideration of patient preferences. It is worth seeing this hierarchy in full, as guides usually only present a fragment of it.

How much does this therapy yield in numbers? A meta-analysis of twenty randomized studies involving 1162 people with chronic insomnia showed that after treatment, the time to fall asleep was shortened by 19.03 minutes, wakefulness after falling asleep was reduced by 26 minutes, and sleep efficiency improved by 9.91 percentage points. Total sleep time increased by 7.61 minutes, but this result did not reach statistical significance. Changes seemed to persist in later measurements, although the authors note that the accuracy of estimates over time was lower. No adverse events were reported (Trauer i wsp., Annals of Internal Medicine, 2015).

One limitation of this meta-analysis is worth knowing, as it narrows the scope of the conclusion. The authors deliberately excluded studies on insomnia coexisting with somatic or mental illness or another sleep disorder to assess the pure effect of therapy. They themselves write that narrow inclusion criteria limit the transferability of the results to patients with such diagnoses. The average age of participants was 56 years, and women made up nearly two-thirds of the sample.

What does cognitive-behavioral therapy for insomnia consist of?

Comprising five components, each with its own justification. The meta-analysis of the effectiveness assumes that cognitive-behavioral therapy for insomnia is considered an approach that combines at least three of the five elements: cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation techniques (Trauer et al., 2015). In the 2021 guidelines, four of them additionally have their own separate recommendations as standalone methods.

Stimulus control restores the association of the bed with sleep. The set of rules is short: the bed is used solely for sleep and sex, after several minutes of unsuccessful lying down, one must get up, and the wake-up time remains constant regardless of when one managed to fall asleep. The guidelines list stimulus control as a method permissible even alone, with a conditional recommendation.

Sleep restriction sounds counterintuitive because it involves shortening the sleep window to how much the patient actually sleeps according to the diary. The goal is to increase sleep pressure and restore its continuity, and the window only extends when sleep becomes consolidated. This method also has a separate conditional recommendation in the guidelines and is nothing more than one element of the whole.

Cognitive therapy works with beliefs that raise tension before sleep: with the compulsion to sleep a certain number of hours and with catastrophic imaginings of the next day. Relaxation techniques reduce physiological arousal and have also been assessed separately, with a conditional recommendation.

The fifth component has a separate status in these guidelines. Sleep hygiene is part of the multi-component therapy, but as a standalone method, it received a negative recommendation. This is a good illustration of how the whole works: elements that give moderate or no effect separately, when combined, create the only behavioral intervention with a strong recommendation.

How to read recommendations in the guidelines?

Two words determine everything here: strong and conditional. Both discussed guidelines from the American Academy of Sleep Medicine were developed using the GRADE method, in which the strength of the recommendation does not indicate the size of the effect for a specific patient, but rather the certainty derived from published data. This is not the same, although it is often confused in press summaries.

A strong recommendation means a course of action that a doctor should apply in most situations. A conditional recommendation requires knowledge and clinical experience, as well as a clear consideration of the patient's preferences when choosing a course of action. In insomnia, there is one behavioral intervention with a strong recommendation, while all others, including those that are effective, have a conditional recommendation.

The authors of the pharmacological guidelines add a caveat worth knowing before considering a weak recommendation as a verdict. The reduction in the quality of evidence rating in the GRADE method is predictable for three reasons independent of the drug itself. Pharmacological studies are usually funded by the manufacturer, which carries the risk of publication bias. The number of studies qualifying for a single substance is small. Results between studies are heterogeneous. Therefore, a weak recommendation is not evidence of ineffectiveness, but rather an expression of lesser certainty.

The opposite is also true and occurs more frequently in guides on natural methods. The absence of a recommendation does not mean that something works. It usually means that no one has properly studied it or that there were too few studies to compile an assessment. A negative suggestion, like that against melatonin or valerian, is, however, an assessment made on existing material, and this is a difference worth remembering when reading the rest of the text.

Is sleep hygiene alone enough for insomnia?

No, and the guidelines state this explicitly. The American Academy of Sleep Medicine suggests not to use sleep hygiene as a standalone treatment for chronic insomnia in adults. This is the only negative recommendation in the entire 2021 document, and it is also the one that guides most often overlook because sleep hygiene is cheap, safe, and sounds reasonable.

The review of the empirical basis for these recommendations starts from the same observation. Its authors begin with the ineffectiveness of sleep hygiene as a treatment in sleep medicine and ask why a set of recommendations, each of which is individually associated with sleep, ceases to work when presented together in the form of education. The conclusion of the review is cautious. Epidemiological and experimental studies support the relationship of individual recommendations with nighttime sleep, but the direct impact of individual recommendations on sleep in the general population remains largely unverified (Irish i wsp., Sleep Medicine Reviews, 2015).

One of the recommendations has undergone strong, direct verification. In a home study, a set dose of caffeine was administered at six hours, three hours, and directly before bedtime. Each of these three variants significantly disrupted sleep compared to placebo, and the scale of the reduction in total sleep time after the dose six hours before sleep was so pronounced that the authors considered it empirical support for the recommendation to stop caffeine at least six hours earlier (Drake i wsp., Journal of Clinical Sleep Medicine, 2013).

How to reconcile this? Sleep hygiene remains as a foundational layer and as an element of multi-component therapy, where it is listed alongside stimulus control, sleep restriction, and working on beliefs. Treated as a standalone treatment for chronic insomnia, it fails, and the guidelines discourage such an attempt.

Do sleeping pills solve the problem?

The pharmacological guidelines are much cooler towards them than sales figures would suggest. The American Academy of Sleep Medicine evaluated individual substances, not entire classes, and assigned a weak recommendation to all of them. This group includes suvorexant, eszopiclone, zaleplon, zolpidem, triazolam, temazepam, ramelteon, and doxepin, each with a designated profile of use: some for difficulties falling asleep, some for maintaining sleep (Sateia i wsp., Journal of Clinical Sleep Medicine, 2017).

A weak recommendation does not mean that a drug is ineffective. It indicates lesser certainty about the outcome and the necessity for an individual decision by the doctor. The authors also explain why the quality of evidence in this area drops almost automatically: pharmacological studies are mostly funded by the manufacturer, the number of studies qualifying for a single substance is small, and the results are heterogeneous.

The second list, that with negative recommendations, is more interesting. The guidelines suggest not to use trazodone, tiagabine, or diphenhydramine in chronic insomnia, which is an antihistamine present in over-the-counter sleeping preparations. On the same negative list are three items commonly considered natural: melatonin, valerian, and tryptophan.

This sets the whole topic differently than most guides do. The division does not run between medication and supplement, but between a method with proven effectiveness and a method whose effectiveness has not been demonstrated. Cognitive-behavioral therapy stands on the side of methods with proven effectiveness, sleeping pills have weak recommendations, and a significant portion of the shelf with natural sleep aids has negative recommendations or none at all.

What is really known about melatonin?

Melatonin is not a sleeping pill, but a hormone that synchronizes the circadian rhythm, and its effect on sleep is modest. A meta-analysis of nineteen placebo-controlled studies, involving 1683 participants with primary sleep disorders, showed a reduction in sleep onset time by 7.06 minutes, an increase in total sleep time by 8.25 minutes, and an improvement in overall sleep quality by 0.22 standardized mean difference (Ferracioli-Oda i wsp., PLoS One, 2013).

One sentence from this work is worth noting because it contradicts the most frequently repeated advice. Longer studies and those using higher doses showed a greater impact on reducing sleep onset and extending sleep. The popular claim that the smallest dose works best, and that a higher dose paradoxically worsens sleep, has no support in this meta-analysis. The authors note, however, that the effect of melatonin does not diminish with continued use and that its side effect profile is mild compared to sleeping pills.

The pharmacological guidelines go further and suggest not to use melatonin in the treatment of chronic insomnia, neither for difficulties falling asleep nor for maintaining sleep. There is no contradiction with the meta-analysis: seven minutes shorter sleep onset is a statistically real change and clinically insignificant for someone who lies awake for an hour.

The practical conclusion is different from what the packaging suggests. Melatonin makes sense where the problem is a shifted circadian rhythm, not where the issue is established arousal in the evening. The choice of preparation and timing for any sleep disorder is up to the doctor, especially for those taking medications regularly. More about the hormone itself is discussed in the text about melatoninie na sen.

Does magnesium shorten the time it takes to fall asleep?

Probably yes, but the evidence is weaker than the popularity of this solution suggests. A systematic review with a meta-analysis found only three randomized studies comparing oral magnesium with placebo, involving a total of 151 older adults with insomnia in three countries. After the intervention, the sleep onset time was shorter by 17.36 minutes than in the placebo group, with a confidence interval from 7.44 to 27.27 minutes (Mah i Pitre, BMC Complementary Medicine and Therapies, 2021).

The second number from this work circulates online without the caveat that invalidates it. Total sleep time increased by 16.06 minutes, but the result was not statistically significant. A statement like "magnesium extends sleep by a quarter of an hour" cites this value as a finding, although the work presents it as a difference that could not be distinguished from chance.

The authors evaluate their material harshly. All three studies had moderate to high risk of systematic error, and the quality of evidence according to the GRADE method was low to very low. The conclusion of the review is straightforward: the quality of the literature is insufficient for a doctor to issue a well-justified recommendation regarding the use of oral magnesium in older adults with insomnia.

What remains practically? A signal worth noting in one age group, cheap and widely available, which the authors write may be supported by evidence from randomized studies for insomnia complaints. This is much less than the promise on the label, but it is not nothing either. In cases of kidney disease, any magnesium supplementation requires prior medical decision.

It is also worth knowing what questions this review does not answer. It included only older adults with insomnia, so it says nothing about younger individuals or those without a diagnosis. It also did not compare different forms of magnesium, and it is precisely around them that most sales promises circulate. The claim that one magnesium salt works better for sleep than another does not come from this work and requires its own source.

Which herbs and adaptogens have evidence?

Ashwagandha has the best results here, while valerian has the worst, and the difference between them is greater than what the common shelf in the store suggests. We have gathered three plants most often described in the context of sleep along with what exactly has been measured about them.

Ashwagandha performs the best. A meta-analysis of five randomized studies involving 400 participants showed a small but significant effect of the extract on overall sleep, with a standardized mean difference of -0.59. The effect was more pronounced in the subgroup of individuals diagnosed with insomnia and with a duration of use of at least eight weeks. There were also improvements in alertness upon waking and levels of anxiety, while quality of life did not change significantly. The authors note that there is insufficient data on serious adverse effects to assess the safety of long-term use (Cheah i wsp., PLoS One, 2021).

Valerian has a more extensive material but a weaker result. A systematic review of sixteen placebo-controlled studies involving 1093 individuals found a significant benefit in six studies reporting sleep as improved or not, with a relative risk of 1.8 and a confidence interval from 1.2 to 2.9. However, the authors note signs of publication bias in this result and significant methodological issues in most studies, and the doses and preparations varied significantly (Bent i wsp., The American Journal of Medicine, 2006). Guidelines from 2017 suggest that valerian should not be used in chronic insomnia.

Passionflower has one decent study, and it needs to be read carefully. It involved 41 healthy individuals aged 18 to 35, with minor fluctuations in sleep quality, not patients with insomnia. The infusion of passionflower consumed for a week resulted in a significantly better assessment of sleep quality than placebo. The authors describe this as a short-term subjective benefit in healthy individuals (Ngan i Conduit, Phytotherapy Research, 2011). More about this plant in a separate text on passionflower for sleep and anxiety.

What do studies say about CBD and CBN in insomnia?

The most frequently cited number on this topic comes from a retrospective case series, not from a randomized study. In a psychiatric clinic, the documentation of 103 adults was reviewed, and the final sample included 72 individuals: 47 presented due to anxiety, 25 due to poor sleep (Shannon et al., The Permanente Journal, 2019).

The results of this series are worth stating accurately, as distorted versions are circulating. Anxiety scores decreased in the first month for 79.2% of individuals and remained at a lower level throughout the observation period. Sleep scores improved in the first month for 66.7%, but fluctuated in the following months. Cannabidiol was well tolerated by all but three patients. The statement about a lasting, three-month effect on sleep, which was previously in this article, has no basis in this work and was removed along with the assigned dose, which the abstract does not provide.

Cannabinol, marketed as the "sleep cannabinoid," performs even worse. A narrative review searched publications for this very promise, reviewed 99 abstracts of studies in humans, and discussed in detail eight works that met the criteria. It found not a single clinical study that assessed the effect of cannabinol on sleep using polysomnography or a validated sleep questionnaire. The author's conclusion is: the published evidence is insufficient to support claims of sleep-inducing effects, and buyers should approach them skeptically (Corroon, Cannabis and Cannabinoid Research, 2021).

There is also a safety aspect, which is more important than efficacy. The panel of the European Food Safety Authority states outright that the safety of cannabidiol cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications simultaneously (EFSA, EFSA Journal, 2026). The third of these groups includes most individuals with chronic insomnia. We discuss this topic more broadly in the text about CBD in the treatment of sleep disorders.

What about L-theanine and other popular sleep supplements?

There are no guidelines for them, which is a different situation than a negative assessment. The pharmacological guidelines from 2017 included three substances considered natural: melatonin, valerian, and tryptophan. Each received a suggestion not to use it in chronic insomnia. L-theanine, glycine, oral GABA, or lavender extract are not mentioned in this document at all.

An earlier version of this article provided specific numbers for some of them: percentages of sleep quality improvement, minutes of reduced sleep onset, proportion of satisfied survey respondents from the store. None of these values could be linked to a study that contained them, so they disappeared along with the sentences that carried them. A survey conducted by the seller is not a study and does not remain in the text in any form.

What does this mean for someone standing in front of the shelf? First, the presence of an ingredient in a sleep preparation does not mean that anyone has measured its effect on sleep in humans. Second, multi-ingredient mixtures make assessment even more difficult, as any potential improvement cannot be attributed to any single ingredient. Third, supplements do not undergo a registration procedure like medications, so the lack of reports of adverse effects may indicate a lack of studies rather than proof of safety.

This does not mean that every such preparation is worthless. It means that its effect remains a hypothesis for now, not an established fact, and that the difference between the two should be clearly visible on the label just like the ingredients.

When to stop taking supplements and see a doctor?

There are situations where seeking a natural way delays the diagnosis of a disease requiring treatment. The first is sleep apnea. The first large screening study in Poland, conducted using the STOP-BANG questionnaire on 613 individuals as part of the PURE project, found a moderate to high risk of obstructive sleep apnea in 66.5% of men and 60.1% of women, which is significantly more often than previously thought (Postrzech-Adamczyk i wsp., Advances in Experimental Medicine and Biology, 2019). This is a screening result, not a diagnosis, and that is why snoring with pauses in breathing requires diagnostics, not herbs.

The second situation is restless legs syndrome. The guidelines from 2025 have changed the recommendations in this area, and it's important to know this because older guides provide the opposite. Strong recommendations were given for gabapentin enacarbil, gabapentin, and pregabalin, as well as intravenous iron carboxymaltose for individuals with an appropriate iron metabolism status. The guidelines suggest against the routine use of pramipexole and ropinirole, and formulate a strong recommendation against cabergoline. Valerian also made it to the negative list (Winkelman i wsp., Journal of Clinical Sleep Medicine, 2025).

The same guidelines recommend regular monitoring of ferritin and transferrin saturation in every patient with clinically significant restless legs syndrome, as the result determines the choice between oral and intravenous iron. The first step should be to eliminate factors that exacerbate symptoms, including alcohol, caffeine, and untreated sleep apnea.

The remaining warning signs are simpler. Daytime sleepiness despite a full night's sleep, symptoms persisting despite the implementation of cognitive-behavioral therapy, nocturnal behaviors such as sleepwalking, and sleep that worsened after starting a new medication are reasons to visit a doctor, not to change a supplement.

How to create a plan for the upcoming weeks?

The order is more important than the choice of the product. The guidelines place cognitive-behavioral therapy first, so a sensible plan starts with its elements, not with shopping. The first two weeks should involve a sleep diary and two behavioral changes with the best-documented effects: a fixed wake-up time and eliminating caffeine at least six hours before sleep.

A sleep diary is not a formality. Without it, you cannot assess whether anything worked, as memory of the night is unreliable, and the subjective feeling of improvement can also occur after a placebo. Record the time you go to bed, the approximate time it takes to fall asleep, wake-ups, the time you get up, and your assessment of restfulness on a simple scale.

The most commonly broken rule of this plan is the weekend. Shifting the wake-up time by two hours on Saturday and Sunday disrupts what was established over the five days, and Monday night then looks like before the plan started. A fixed wake-up time applies seven days a week, even after a bad night, as it is the anchor of the circadian rhythm.

The third and fourth weeks involve full control of stimuli, meaning the bed is used exclusively for sleep and sex, getting out of bed after several minutes of unsuccessful lying down, and a fixed wake-up time regardless of what time you managed to fall asleep. Only against this backdrop does it make sense to consider adding one supplement, always individually, so that its impact can be assessed. Evening combinations are discussed separately in the evening supplementation protocol.

After four weeks comes the moment of decision. If the diary shows shorter time to fall asleep and fewer awakenings, the plan is working and should be maintained for the following weeks. If nothing has changed, adding more supplements rarely helps and more often delays the conversation with a doctor about secondary causes: thyroid disease, iron deficiency, depression, chronic pain, or the effects of the medication being taken.

Frequently Asked Questions

Which method for insomnia has the strongest evidence?

Multicomponent cognitive-behavioral therapy for insomnia. This is the only behavioral intervention with strong recommendations in the guidelines of the American Academy of Sleep Medicine from 2021. A meta-analysis of twenty randomized studies with 1162 participants showed a reduction in sleep onset time by 19 minutes and a decrease in wakefulness after sleep onset by 26 minutes, with no adverse events.

Is sleep hygiene enough to cure insomnia?

No. The guidelines from 2021 suggest not using sleep hygiene as a standalone treatment for chronic insomnia in adults. This is the only negative recommendation in the document. Sleep hygiene remains a foundational layer and part of a multi-component therapy, but it does not treat chronic insomnia on its own.

How much does melatonin provide according to meta-analyses?

Not much. In a meta-analysis of nineteen placebo-controlled studies involving 1683 people, melatonin shortened the time to fall asleep by 7.06 minutes and increased total sleep time by 8.25 minutes. Longer studies with higher doses yielded greater effects, not lesser ones. The pharmacological guidelines from 2017 suggest not using it for chronic insomnia.

Does magnesium really help with sleep?

Partially. In a meta-analysis of three randomized studies involving 151 older adults, magnesium shortened the time to fall asleep by 17.36 minutes compared to placebo. The increase in sleep duration of 16.06 minutes was not statistically significant. All studies had moderate to high risk of bias, and the quality of evidence was rated as low to very low.

Where does the figure of 66% improvement in sleep after CBD come from?

From a retrospective case series involving 72 adults, of whom 25 reported poor sleep. Sleep scores improved in the first month for 66.7%, but fluctuated in subsequent months. Anxiety scores decreased for 79.2% and remained lower. This was not a randomized study.

Does cannabinol help with sleep?

Published evidence for this is insufficient. A 2021 review searched the literature for this promise and found no clinical studies assessing the impact of cannabinol on sleep using polysomnography or validated questionnaires. The author recommends skepticism towards claims made by manufacturers of sleep products.

When does insomnia require a doctor's visit?

When snoring with breathing pauses occurs, daytime sleepiness despite a full night’s sleep, unpleasant sensations in the legs worsening in the evening, or nocturnal behaviors like sleepwalking, or when sleep worsens after starting a new medication. In these situations, supplements delay the diagnosis of a condition requiring different treatment.

Plant extracts supporting evening regeneration, including ashwagandha, can be found in the section adaptogens in the u Bucha store.

This article is for informational and educational purposes and does not constitute medical advice. Before starting supplementation, consult your doctor, especially if you are taking medications regularly, are pregnant or breastfeeding, or have a chronic illness.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-10